Radiation Toxicity Clinical Trial
— THYRO-RTOfficial title:
Phase II Randomized Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers.
NCT number | NCT03669432 |
Other study ID # | 1076 |
Secondary ID | |
Status | Active, not recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2013 |
Est. completion date | July 2026 |
Verified date | April 2022 |
Source | Tata Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial deals with cancers of the thyroid gland which are advanced at the local site of thyroid. These cancers are treated with surgery and complete removal of the thyroid gland. But due to advanced nature, there is risk of re-occurrence. Radiotherapy can be used to prevent this re-occurrence. This study attempt to see the effect of radiotherapy in preventing re-occurrence and its side effects in advanced thyroid cancer.
Status | Active, not recruiting |
Enrollment | 72 |
Est. completion date | July 2026 |
Est. primary completion date | July 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: A) All patients of differentiated thyroid cancer (papillary/follicular/poorly differentiated/) who have undergone total/completion thyroidectomy at our institute and having at least two of the following features (listed below) intra-operatively and/or on histopathology 1. Gross extrathyroidal spread into soft tissues of the neck, trachea, esophagus, recurrent laryngeal nerve (constituting stage T4a) 2. R1/ shave resections (minimal residual disease) 3. R2 resections (gross residual disease) 4. Multiple lymph nodes positive(>2) with perinodal extension at level VI B) Normal baseline haematological and biochemical parameters. Exclusion Criteria: 1. Anaplastic or medullary thyroid cancer 2. Previous history of radiation 3. Pregnancy 4. < 18 years Patient unwilling to participate in the study. |
Country | Name | City | State |
---|---|---|---|
India | Gouri Pantvaidya | Mumbai | Maharashtra |
Lead Sponsor | Collaborator |
---|---|
Tata Memorial Hospital | Department of Atomic Energy |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | locoregional recurrence | locoregional recurrence is defined as occurrence of pathology proven recurrence in the neck | after completion of treatment- till 5 years | |
Secondary | acute toxicity | Acute toxicity will be measured during and after completion of radiation (3 months). | during treatment- till 23 months | |
Secondary | late toxicity | Late toxicity will be measured using the LENT-SOMA scale | at 2 years after treatment completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT02058550 -
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
|
Phase 1 | |
Completed |
NCT01399372 -
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
|
Phase 2 | |
Completed |
NCT01434290 -
Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT01407770 -
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
|
||
Completed |
NCT00003313 -
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT03783364 -
Pre- or Postoperative Accelerated Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT04305613 -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
|
||
Recruiting |
NCT06036706 -
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
|
N/A | |
Withdrawn |
NCT04593914 -
A Novel Skin Barrier Protectant for Acute Radiodermatitis
|
N/A | |
Recruiting |
NCT04110223 -
Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
|
||
Active, not recruiting |
NCT02259218 -
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
|
||
Recruiting |
NCT06073509 -
Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
|
||
Withdrawn |
NCT02017925 -
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
|
N/A | |
Completed |
NCT01170299 -
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
|
N/A | |
Completed |
NCT00974168 -
Spinal Cord Compression Re-Treat Study
|
Phase 2 | |
Completed |
NCT00008398 -
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
|
Phase 3 | |
Enrolling by invitation |
NCT04047823 -
Temperature and Injury in Radiotherapy Radiation Skin Injury
|